Institute for Urologic Oncology
Tumor Repository Launched
Advancements have been made in the treatment of clear cell kidney cancer over the past decade largely due to efforts characterizing the disease through laboratory research. However, for rare kidney cancers such as those found with hereditary leiomyomatosis and renal cell cancer (HLRCC), most centers only evaluate and treat a small number of patients each year limiting the ability of academic centers to access biological specimens to study the cancers and develop possible treatments.
Advances in Radiation Technology
A new advance in radiation-therapy equipment is giving physicians the ability to better visualize tumors and internal anatomy, allowing more accurate delivery of necessary treatments. The equipment, called the MRIdian LINAC, is an improvement over older technologies, because it uses a built-in MRI to guide radiation treatment in real time. This form of external beam radiation therapy allows radiation oncologists to provide treatment while reducing the exposure of healthy tissues. The MRIdian is available only at a limited number of major medical centers, including UCLA, where it is being used in multiple clinical trials for prostate cancer, pancreatic cancer and sarcomas. Amar Kishan, MD, UCLA Health radiation oncologist and IUO member, is leading this effort.
New FDA Approval Received
From the joint efforts of two groups led by the nuclear medicine teams at UCLA and UCSF comes an important achievement that is likely to change patient care for men with prostate cancer. On December 1st, 2020 the FDA approved Gallium 68 PSMA-11 (68Ga-PSMA-11) for positron emission tomography (PET) imaging of prostate cancer.
Prostate Cancer Award
A team led by Paul C Boutros, PhD, MBA, professor in the departments of human genetics and urology and interim vice dean for research at the David Geffen School of Medicine at UCLA and director of the UCLA Jonsson Comprehensive Cancer Center’s Cancer Data Science program has been awarded over $2.7 million in research funding from the U.S. Department of Defense to support two projects that will use computational models and DNA sequencing to improve prostate cancer treatment outcomes. The project is co-led by Huihui Ye, MD, MS, chief of Genitourinary Pathology at UCLA.
Clinical Trials Spotlight
UCLA Health has a phase II trial that investigates how well pamiparib and temozolomide work in treating patients with hereditary leiomyomatosis and renal cell (kidney) cancer. Brian Shuch, MD, Associate Professor of Urology, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research, is the principal investigator.
Cancer and COVID-19
Please take extra measures to help protect yourself and reduce the transmission of the disease. This is particularly important for people with cancer. What everyone needs to know about COVID-19 (vaccine updates, getting testing, positive test results).
What You Should Know
Read about precautions cancer patients need to take.